Amoy Diagnostics Co Ltd - Asset Resilience Ratio
Amoy Diagnostics Co Ltd (300685) has an Asset Resilience Ratio of 12.36% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Amoy Diagnostics Co Ltd (300685) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Amoy Diagnostics Co Ltd's Asset Resilience Ratio has changed over time. See Amoy Diagnostics Co Ltd (300685) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Amoy Diagnostics Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Amoy Diagnostics Co Ltd (300685) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥277.65 Million | 12.36% |
| Total Liquid Assets | CN¥277.65 Million | 12.36% |
Asset Resilience Insights
- Moderate Liquidity: Amoy Diagnostics Co Ltd has 12.36% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Amoy Diagnostics Co Ltd Industry Peers by Asset Resilience Ratio
Compare Amoy Diagnostics Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB |
Diagnostics & Research | 43.99% |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193 |
Diagnostics & Research | 55.11% |
|
Diagnos Laboratorium Utama PT Tbk
JK:DGNS |
Diagnostics & Research | 0.32% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Amoy Diagnostics Co Ltd (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Amoy Diagnostics Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 17.04% | CN¥351.89 Million ≈ $51.49 Million |
CN¥2.06 Billion ≈ $302.15 Million |
-7.20pp |
| 2023-12-31 | 24.25% | CN¥469.12 Million ≈ $68.65 Million |
CN¥1.93 Billion ≈ $283.13 Million |
+8.54pp |
| 2022-12-31 | 15.71% | CN¥259.30 Million ≈ $37.94 Million |
CN¥1.65 Billion ≈ $241.58 Million |
-5.08pp |
| 2021-12-31 | 20.78% | CN¥315.85 Million ≈ $46.22 Million |
CN¥1.52 Billion ≈ $222.41 Million |
-2.80pp |
| 2020-12-31 | 23.58% | CN¥304.86 Million ≈ $44.61 Million |
CN¥1.29 Billion ≈ $189.19 Million |
+20.71pp |
| 2019-12-31 | 2.87% | CN¥30.06 Million ≈ $4.40 Million |
CN¥1.05 Billion ≈ $153.18 Million |
+2.86pp |
| 2018-12-31 | 0.01% | CN¥90.36K ≈ $13.22K |
CN¥818.75 Million ≈ $119.81 Million |
-- |
About Amoy Diagnostics Co Ltd
Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive … Read more